Form D · Biotechnology
Gemini Therapeutics, Inc.
Cambridge, MA · CIK 0001672981
Offering snapshot reported May 2, 2016 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 19, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 2, 2016 | Initial | $2,000,001 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-262383
Convertible Notes
Source: Form D, filed May 2, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jean George | Director |
| Carl Gordon | Director |
| James Mc Laughlin | Director, Executive |
| Jason Rhodes | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
36 Irving Street, #3
Cambridge, MA, 02138
Cambridge, MA, 02138